Total: $59.8M |
||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Advanced Viral Research Corp. (OTC BB:ADVR) | Credit line financing | | | Company said the original deal for a $20M equity line of credit was increased to $50M; the credit line was constructed by The May Davis Group (2/16) |
Antares Pharma (Switzerland; MEDJ) | Private placement of common shares | 1.2S (plus warrants to purchase 0.3S) | US$7 | Antares Pharma completed a US$7M private placement; participants included several banks and institutional investors (2/6) |
BioMarin Pharmaceutical Inc. (BMRN) | Equity financing | ND | $1 | BioMarin entered into an agreement with Acqua Wellington North American Equities Fund Ltd. for equity funding of up to $50M over the next 20 months; the agreement includes an initial purchase of $1M of common stock by Acqua Wellington (2/1) |
BioPulse International Inc. (OTC BB:BIOP) | Bridge financing | ND | $3 | BioPulse completed a $3M bridge financing; terms were not disclosed (2/7) |
Columbia Laboratories Inc. (AMEX:COB) | Equity financing | ND | | Columbia entered an equity financing agreement with Acqua Wellington North American Equities Fund Ltd. for up to $20M over a 24-month period (2/8) |
Heska Corp. (HSKA) | Private placement of common shares | 4.57S | $5.7 | Heska raised $5.7M in a private placement in which Wells Fargo Van Kaspar acted as financial adviser (2/7) |
Igen International Inc. (IGEN) | Equity financing | | $3 | Igen entered into a $60M, 28-month equity financing facility with Acqua Wellington North American Equities Fund Ltd. that called for an initial equity financing of $3M (2/12) |
La Jolla Pharmaceutical Co. (LJPC) | Private placement of common stock | 5.7S | $35.3 | J.P. Morgan Partners (formerly Chase Capital Partners) was the lead investor; La Jolla has about 35M shares outstanding after the placement; Pacific Growth Equities Inc. served as placement agent (2/6) |
NeoTherapeutics Inc. (NEOT) | Private placement of common stock | 1.6S | $3.5 | NeoTherapeutics sold 1.6M shares to Amro International at a 15% discount to the market price, raising $3.5M (2/15) |
NexMed Inc. (NEXM) | Line of credit | | | NexMed entered into an agreement with a U.S. financial institution for a $5M line of credit (2/21) |
Pheromone Sciences Corp. (Canada; CDNX:PHS) | Special warrant private placement | 2W | C$2 US$1.31 | Pheromone raised US$1.31M in the placement of 2M special warrants, each exercisable into one common share and half of a warrant (2/26) |
Samaritan Pharmaceuticals (OTC BB:SPHC) | Equity financing | ND | | Samaritan gained access to $20M in funding through Fusion Capital Fund II LLC; Fusion will buy $400,000 worth of Samaritan stock per month until the $20M is exhausted; this is an amended deal to one made in November for $10M in funding (2/7) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Non-U.S. currencies were converted at the exchange rate on the date of the announcement. |
||||
@ Dates refer to the date of the press release. |
||||
ASX = Australian Stock Exchange |
||||
LSE = London Stock Exchange |
||||
TSE = Toronto Stock Exchange |
||||
VSE = Vancouver Stock Exchange |
||||
OTC BB = Over The Counter Bulletin Board |
||||
